A Research Guide for
Balance & Dizziness Disorders

BPPV is the single most common cause of vertigo, responsible for roughly one in four cases. It occurs when tiny calcium carbonate crystals (called otoconia or “ear rocks”) break loose from the utricle and drift into one of the semicircular canals, where they do not belong. When you move your head — rolling over in bed, looking up, or bending down — the displaced crystals shift and send a false signal to the brain that the head is spinning.

Characteristic symptoms:

• Brief episodes of intense spinning vertigo (usually lasting less than 60 seconds) triggered by specific head movements
• Most commonly triggered by rolling over in bed, looking up, or bending forward
• May cause nausea but usually no hearing loss or ear ringing
• Can recur — roughly 15% per year, about 50% over five years

Diagnosis: The Dix-Hallpike test is the gold standard. The doctor moves your head into specific positions while watching your eyes for a characteristic pattern of nystagmus (involuntary eye movements). The posterior canal is affected in 80–90% of cases. The horizontal canal is involved in 5–15%, which requires a different test (the supine roll test).

Critical point: BPPV is massively underdiagnosed in primary care. Many patients receive only meclizine (a vestibular suppressant), which does not treat the underlying problem — it only masks symptoms and may actually delay the brain’s natural compensation. If you have been given only medication for positional vertigo, ask specifically about repositioning maneuvers.

Vestibular migraine is one of the most common causes of recurrent vertigo, affecting an estimated 1–2.7% of the population. It is frequently missed because many people associate migraine only with severe headache — but vestibular migraine can cause vertigo with mild headache, or even without headache at all.

Diagnostic criteria (Barany Society / International Headache Society, 2012):

• At least 5 episodes of vestibular symptoms of moderate-to-severe intensity, lasting 5 minutes to 72 hours
• A current or past history of migraine (with or without aura)
• At least one migraine feature during 50% or more of the vestibular episodes: headache, light sensitivity, sound sensitivity, or visual aura
• Not better explained by another vestibular or headache diagnosis

Characteristic symptoms:

• Episodes of spontaneous or positional vertigo, head-motion intolerance, or visually induced dizziness
• Often accompanied by sensitivity to light, sound, or visual patterns
• Episodes may be preceded by visual aura in some patients
• Can co-exist with BPPV and Meniere’s disease, complicating the picture

Diagnosis is primarily clinical — based on the history and meeting the criteria above. There is no specific test that confirms vestibular migraine, which is why it is often missed on the first visit.

Meniere’s disease is caused by an abnormal buildup of fluid (endolymphatic hydrops) in the inner ear. It typically affects one ear, though 25–50% of patients develop involvement in both ears over time.

AAO-HNS 2020 diagnostic criteria for definite Meniere’s disease:

• Two or more spontaneous vertigo episodes lasting 20 minutes to 12 hours
• Low-to-medium frequency sensorineural hearing loss in the affected ear, documented on a hearing test
• Fluctuating ear symptoms in the affected ear: hearing changes, tinnitus (ringing), or a feeling of fullness or pressure

The classic triad of symptoms:

• Vertigo attacks — intense spinning episodes lasting minutes to hours, often with nausea and vomiting
• Hearing loss — fluctuating at first (low frequencies affected earliest), potentially progressive over years
• Tinnitus and aural fullness — ringing, buzzing, or a plugged feeling in the affected ear, often worsening before or during attacks

Diagnosis requires a hearing test (audiogram) and a careful history. Advanced MRI techniques using gadolinium contrast can now directly visualize endolymphatic hydrops, which is improving diagnostic certainty.

PPPD is a relatively recently defined condition (Barany Society, 2017) that accounts for a large proportion of patients seen at specialized dizziness clinics. It typically develops after an acute vestibular event — such as a bout of BPPV, vestibular neuritis, a panic attack, or a concussion — and persists long after the original trigger has resolved.

Key features:

• Chronic dizziness, unsteadiness, or non-spinning vertigo lasting three months or more
• Symptoms are present most days and usually last for hours
• Worsened by being upright, by active or passive motion, and by complex visual environments (grocery stores, scrolling screens, busy traffic)
• The original triggering event may have fully resolved, but the dizziness continues

A critical point: PPPD is not “psychogenic dizziness” or “all in your head.” Research has demonstrated measurable neurophysiological changes in how the brain processes balance information. The brain has essentially become stuck in a heightened state of motion sensitivity that was initially an appropriate response to the triggering event. Understanding this helps remove the stigma that too many PPPD patients face.

Vestibular neuritis is a sudden loss of function in one vestibular nerve, most likely caused by a viral infection or post-viral inflammation. It causes the most dramatic acute vertigo episode most patients will ever experience.

Symptoms:

• Sudden onset of severe, constant vertigo lasting days (not brief episodes)
• Severe nausea and vomiting
• Difficulty walking (veering to the affected side)
• No hearing loss (this distinguishes it from labyrinthitis)

Labyrinthitis involves the same process but additionally affects the cochlea (hearing organ), causing hearing loss alongside the vertigo.

The acute phase is intense but self-limited. Most patients improve substantially within days to weeks as the brain begins to compensate. Treatment includes short-term vestibular suppressants for symptom relief (used only for the first 2–3 days to avoid delaying compensation), and corticosteroids (methylprednisolone) within 72 hours may improve recovery. Early vestibular rehabilitation is critical for full recovery.

Most vertigo is caused by benign conditions, but acute vertigo can occasionally be the first sign of a stroke affecting the brainstem or cerebellum (posterior circulation). This is the most important safety message in this guide:

The HINTS concept for patients: In the emergency department, doctors can use a bedside examination called HINTS (Head Impulse, Nystagmus, Test of Skew) to help distinguish a stroke from vestibular neuritis. When performed by a trained specialist, this exam is highly accurate — in some studies, more sensitive than an early CT scan.

Critical fact: A CT scan of the brain detects only about 16% of strokes in the back part of the brain (posterior fossa) within the first 24 hours. If you are in the emergency department with acute severe vertigo and your CT is “normal,” this does not rule out a stroke. If there are any concerning features, MRI or specialist consultation should be pursued. Advocate for yourself or have someone advocate for you.

If your doctor suspects a vestibular disorder, you may be referred for specialized testing. Here is what the common tests involve:

• Videonystagmography (VNG) — You wear goggles with infrared cameras that record your eye movements while you follow visual targets, move your head into different positions, and have warm and cool air or water placed in each ear canal. This maps how each inner ear is functioning. The caloric test (warm/cool air) can be temporarily dizzying but is valuable information.
• Video Head Impulse Test (vHIT) — You focus on a target while the examiner makes quick, small head turns. The goggles track whether your eyes keep up with the head movement. This tests each semicircular canal individually and is quick and painless.
• Vestibular Evoked Myogenic Potentials (VEMP) — Sensors placed on your neck or near your eyes measure muscle responses to loud clicks or vibrations. This tests the otolith organs and is particularly useful for diagnosing superior canal dehiscence (SSCD).
• Audiogram (hearing test) — Essential for diagnosing Meniere’s disease and acoustic neuroma, and useful as a baseline for many vestibular conditions.
• MRI of the brain and internal auditory canals — Used to rule out acoustic neuroma, check for signs of stroke or multiple sclerosis, and in some centers to visualize endolymphatic hydrops in Meniere’s disease.

Not every patient needs every test. Your specialist will choose tests based on your symptoms and history. Bring a list of your medications, as some can affect test results and may need to be paused beforehand.

Almost everyone who steps off a boat after a few days at sea feels the ground sway for a little while — the brain has adapted to constant motion and needs a few hours to readjust. In Mal de Débarquement Syndrome (MdDS), that sensation does not switch off. People describe a persistent rocking, swaying, or bobbing — as if they are still on the boat — lasting weeks, months, or occasionally years after a cruise, a long flight, or even a long car journey.

A few features make MdDS distinctive and help doctors recognize it:

• The sensation is one of self-motion (rocking/swaying), not spinning vertigo.
• It paradoxically improves with passive motion — many people feel better while driving or riding in a car and worse when sitting still or lying down.
• It usually follows exposure to motion (the “classic” form), though a spontaneous form without a clear motion trigger also exists.

MdDS is not dangerous and is not a sign of brain damage, but it can be genuinely disabling and is frequently dismissed or misdiagnosed. The exact cause is still being worked out; the leading theory is that the brain’s normal adaptation to rhythmic motion fails to “reset.” Treatment evidence is limited, but a specialized re-adaptation protocol (rolling the head while watching moving stripes, developed by Dr. Mingjia Dai) has shown promise in research, and vestibular rehabilitation, certain medications used for related conditions, and reassurance all have a role. If you have lingering rocking after travel, seek a clinician familiar with MdDS — being believed and correctly diagnosed is often the first relief.

Dizziness and imbalance are among the most common symptoms after a concussion (mild traumatic brain injury), and they are one of the strongest predictors of a slower recovery. After a head impact, dizziness can come from several sources at once, which is why a careful assessment matters:

• Traumatic BPPV — head trauma can dislodge inner-ear crystals, producing classic positional vertigo that is curable with repositioning. This is always worth checking after a concussion because it is so treatable.
• Vestibular dysfunction — the impact can disrupt how the inner ear and brain process motion, causing dizziness with head movement and difficulty stabilizing vision.
• Visual and oculomotor problems — the eye-movement system is frequently affected, causing dizziness when reading, scrolling, or in busy environments.
• PPPD — a concussion is a recognized trigger for persistent postural-perceptual dizziness, in which the symptoms outlast the original injury.

The encouraging news is that vestibular rehabilitation is effective for concussion-related dizziness, and the modern approach favors active, guided rehabilitation over prolonged rest. A 2025 systematic review confirmed that targeted vestibular therapy significantly improves dizziness and balance and can speed return to work, school, and sport. If dizziness lingers more than a few weeks after a head injury, ask for referral to a vestibular therapist or a concussion clinic experienced in balance problems.

Many people with neck pain and stiffness also feel dizzy or unsteady, and it is natural to assume the two are connected. “Cervicogenic dizziness” — dizziness attributed to the neck — is a real concept, but it is also one of the most over-diagnosed and controversial labels in this field, and it is important to understand why.

There is no specific test that proves dizziness is coming from the neck. The diagnosis is one of exclusion — meaning it should only be considered after the more common and more treatable causes (BPPV, vestibular migraine, Meniere’s, PPPD, inner-ear and central causes, and blood-pressure problems) have been properly ruled out. In practice, a great many people labeled with “cervicogenic dizziness” turn out to have vestibular migraine or PPPD, both of which have far better-defined treatments. Neck problems and these vestibular conditions also commonly coexist, which muddies the picture further.

If genuine neck-related dizziness is suspected after a thorough work-up, treatment focuses on the neck itself — physiotherapy, manual therapy, posture and movement retraining, and pain management — often combined with vestibular rehabilitation. The key message: do not let “it’s just your neck” close the door on a complete vestibular evaluation, because a missed vestibular migraine or BPPV is a treatable diagnosis hiding behind a vague label.

• What do you think is causing my dizziness or vertigo?
• Has BPPV been ruled out with a Dix-Hallpike test?
• Could this be vestibular migraine, even if my headaches are mild?
• Do I need vestibular testing (VNG, vHIT, VEMP), and what will each test tell us?
• Should I have a hearing test?
• Do I need an MRI to rule out a more serious cause?
• Is there any chance this could be related to my medications?
• Should I see a vestibular specialist (neuro-otologist or neurotologist)?
• How long should I expect the diagnostic process to take?
• What should I do if symptoms suddenly worsen or new symptoms appear?

BPPV is unique among vestibular disorders in that it can often be cured with a physical maneuver performed in a single office visit. Different canals require different maneuvers:

• Posterior canal BPPV (most common, 80–90% of cases): The Epley maneuver is the gold standard. Your doctor guides your head through a series of positions that move the displaced crystals out of the semicircular canal and back to where they belong. It cures about 80% of patients on the first attempt and over 95% with repeated treatments. The Semont maneuver is an alternative approach for posterior canal BPPV.
• Horizontal (lateral) canal BPPV (5–15% of cases): The BBQ roll (Lempert maneuver) is used, involving a series of 90-degree turns while lying down. There are two variants of horizontal canal BPPV (geotropic and apogeotropic), requiring slightly different approaches.
• Anterior canal BPPV (rare, <2%): Deep head-hanging maneuvers or reverse Epley can be used; these cases often resolve spontaneously.

After treatment: You may feel mildly unsteady for a day or two after a successful repositioning, which is normal. Recurrence is possible (about 15% per year), and the maneuver can simply be repeated. Some patients learn a modified version to perform at home under their doctor’s guidance.

The AAO-HNS 2017 guideline strongly recommends the Dix-Hallpike test for diagnosis and canalith repositioning procedures for treatment. This guideline remains current.

Vestibular rehabilitation is an exercise-based treatment program delivered by physiotherapists with specialized training in vestibular disorders. It is the evidence-based cornerstone of treatment for most vestibular conditions, supported by Cochrane reviews showing moderate to robust evidence of efficacy.

The three components of VRT:

• Gaze stabilization exercises — Train the brain to keep vision clear during head movement. You practice focusing on a target while moving your head, progressing from slow to fast movements and from simple to complex backgrounds.
• Habituation exercises — Gradually reduce dizziness triggered by specific movements or visual environments through repeated, controlled exposure. The brain learns to stop overreacting to these stimuli.
• Balance retraining — Progressive challenges to standing and walking balance, including exercises on different surfaces, with eyes open and closed, and during dual-task activities (such as walking while talking).

What to expect: A typical VRT program lasts 6–12 weeks, with supervised sessions (usually weekly or biweekly) plus daily home exercises lasting 20–30 minutes. Exercises should feel mildly to moderately challenging — not unbearable, but not easy either. The brain adapts through neuroplasticity, and exercises that are too easy will not drive compensation.

VRT is effective for: vestibular neuritis recovery, chronic BPPV, post-surgical rehabilitation (after labyrinthectomy or other ear surgery), bilateral vestibular loss, PPPD, concussion-related dizziness, and age-related balance decline.

An important barrier: Access to qualified vestibular physiotherapists remains limited. Many patients are never referred. If your doctor has not mentioned VRT, ask about it specifically.

Walking into vestibular rehabilitation for the first time can be intimidating, especially if movement makes you dizzy. Knowing what happens helps:

• A detailed assessment comes first. The therapist will ask about your symptoms and triggers, then test your balance, eye movements, gaze stability during head turns, walking, and how you respond to specific movements and positions. This builds a personalized picture — vestibular rehab is not a generic exercise class.
• The exercises are designed to provoke mild symptoms — on purpose. This is the part that surprises most people. The brain only adapts when it is gently challenged, so exercises that bring on a little dizziness are doing their job. The goal is mild-to-moderate symptoms that settle within a few minutes — not symptoms so severe you cannot function. Tell your therapist how each exercise feels so they can fine-tune the difficulty.
• You will get a home program. The real work happens between visits. Most programs involve 10–20 minutes of exercises once or twice a day. Consistency at home, more than the number of clinic visits, is what determines how well you do.
• Progress is gradual, not instant. Most people notice meaningful improvement over 6–12 weeks. There may be ups and downs along the way; a harder day does not mean you are getting worse.

If an exercise consistently leaves you severely dizzy for hours, that is a signal to adjust — not to quit. Contact your therapist; the program can almost always be modified to a level you can tolerate while still making progress.

Several exercises can be done at home, but they work best when chosen and taught by a professional for your specific diagnosis. Doing the wrong exercise for your condition — or the right one incorrectly — can be unhelpful or briefly worsen symptoms. Always confirm with your doctor or therapist which of these fits you:

• Brandt-Daroff exercises — A series of movements from sitting to lying on each side, repeated several times, traditionally used for BPPV and for habituating motion sensitivity. They are less effective than an in-office Epley maneuver for curing posterior-canal BPPV, but can help with residual dizziness and as a home habituation tool. Your clinician can show you the correct technique.
• Gaze stabilization (“VOR”) exercises — Focusing on a fixed target (such as a letter on the wall) while moving your head side to side and up and down, progressing from slow to faster movements. These retrain the reflex that keeps vision clear during head motion and are central to recovering from one-sided vestibular loss.
• Habituation exercises — Repeating the specific movements or visual situations that bring on your dizziness, in a controlled way, so the brain gradually stops over-reacting. This is especially important for PPPD and visually-triggered dizziness.
• Balance exercises — Standing with feet together or one in front of the other, with eyes open and then closed, on firm and then softer surfaces — always near a wall or sturdy chair for safety.

Safety first: Do balance exercises within reach of something solid to hold, and ideally with someone nearby when you are starting out. If a movement makes you feel faint (rather than dizzy), or brings on chest pain, severe headache, or any stroke warning sign, stop and seek medical advice.

Sometimes the simplest way to feel steadier is to subtract a medication rather than add one. A surprising number of common drugs can cause or worsen dizziness, lightheadedness, and falls — especially in older adults taking several medicines. Worth reviewing with your doctor or pharmacist:

• Blood pressure medications and water pills (diuretics) — can drop your blood pressure too far, particularly on standing, causing lightheadedness.
• Sedatives and sleep aids — benzodiazepines (such as diazepam, lorazepam) and “Z-drugs” cause drowsiness and unsteadiness and, used long-term, actually slow vestibular recovery.
• Older antihistamines — including the very vestibular suppressants (like meclizine) sometimes over-prescribed for dizziness; helpful briefly, harmful long-term.
• Some antidepressants, nerve-pain medications, and muscle relaxants — can add sedation and affect balance.
• Certain antibiotics and chemotherapy drugs — a small number (notably the “-mycin” aminoglycoside antibiotics and platinum chemotherapy) can damage the inner ear itself; this risk is managed carefully by your medical team when these drugs are necessary.

Never stop a prescribed medication on your own — some need to be tapered, and the underlying condition still needs treating. Instead, bring a complete list of everything you take (including over-the-counter products and supplements) to your appointment and ask: “Could any of these be contributing to my dizziness, and is there a safer alternative?”

Medications play different roles in different vestibular conditions. Understanding these distinctions matters:

Vestibular suppressants (meclizine, dimenhydrinate, benzodiazepines):

• Reduce the brain’s response to abnormal vestibular signals, easing nausea and vertigo intensity
• Appropriate for short-term use during acute episodes (2–3 days maximum for most conditions)
• Extended use is harmful for most vestibular conditions because it delays the brain’s natural compensation — the brain cannot learn to adapt if the signals are being suppressed
• Meclizine does NOT treat BPPV; it only masks symptoms. Repositioning is the treatment.

Betahistine (for Meniere’s disease):

• The most prescribed vestibular medication worldwide (Europe, UK, Japan, Australia, Latin America)
• Not FDA-approved in the United States due to insufficient efficacy evidence
• A major clinical trial (BEMED, 2016) comparing betahistine at two doses against placebo found no significant difference in vertigo attack rates
• Despite this, it is widely used outside the US based on clinical experience and earlier positive studies
• US patients can access betahistine through compounding pharmacies

Diuretics (for Meniere’s disease): Hydrochlorothiazide with triamterene is commonly used to reduce inner ear fluid, though high-quality evidence is limited.

Migraine preventives (for vestibular migraine):

• Beta-blockers (propranolol), tricyclic antidepressants (amitriptyline, nortriptyline), venlafaxine (SNRI), and topiramate are the main options
• No drug is specifically FDA-approved for vestibular migraine, but these are well-established migraine preventives
• CGRP monoclonal antibodies (such as galcanezumab) are under investigation for vestibular migraine
• Treatment may need 2–3 months at an adequate dose before full benefit is seen

SSRIs and SNRIs (for PPPD): Sertraline and venlafaxine are the most studied; roughly 64% of patients respond. Medication should be combined with VRT and CBT for the best outcomes.

When dietary and oral medication approaches do not adequately control Meniere’s vertigo, injections through the eardrum (intratympanic therapy) represent the next step on the treatment ladder:

• Intratympanic dexamethasone — A steroid injected through the eardrum into the middle ear space. It is non-ablative (does not destroy vestibular function), preserves hearing, and is effective for acute flares and as maintenance therapy for refractory cases. It can be repeated as needed.
• Intratympanic gentamicin — An aminoglycoside antibiotic that is selectively toxic to vestibular cells. It reduces vertigo by partially disabling the overactive inner ear. A meta-analysis found an 88.6% treatment success rate, but a 47.1% relapse rate and a risk of additional hearing loss. This is considered a partially ablative (destructive) treatment and is reserved for unilateral Meniere’s disease that has not responded to less aggressive approaches.

The choice between dexamethasone and gentamicin depends on the severity of vertigo, the current hearing level, whether the disease is unilateral, and the patient’s preferences. Most specialists now try dexamethasone first before considering gentamicin.

For Meniere’s disease:

• Low-sodium diet (<1,500–2,000 mg per day) — the single most recommended dietary change; aims to reduce endolymphatic fluid pressure
• Adequate hydration — evenly distributed throughout the day
• Reduce or eliminate caffeine and alcohol, which may worsen symptoms
• Avoid monosodium glutamate (MSG) in sensitive individuals

For vestibular migraine:

• Identify and avoid migraine triggers: specific foods (aged cheese, chocolate, processed meats, alcohol — especially red wine), irregular sleep, skipped meals, dehydration, stress, and hormonal changes
• Maintain a regular sleep schedule — both too little and too much sleep can trigger episodes
• Regular moderate exercise (30 minutes most days) has evidence as a migraine preventive
• Stress management techniques: mindfulness, progressive relaxation, yoga

For all vestibular conditions:

• Limit alcohol, which directly impairs vestibular function
• Review all medications with your doctor — many common drugs (blood pressure medications, antidepressants, anticonvulsants, sedatives) can worsen dizziness
• Stay physically active within your limits — inactivity worsens balance over time

Surgery is reserved for patients who have not responded adequately to conservative treatments. The options vary by condition:

For Meniere’s disease:

• Endolymphatic sac decompression or shunt — A procedure to reduce fluid pressure in the inner ear. Less invasive than other surgical options, with variable success rates but generally favorable for many patients.
• Vestibular nerve section — Cutting the vestibular nerve to stop vertigo signals while preserving hearing. Highly effective for vertigo control but requires neurosurgery.
• Labyrinthectomy — Complete removal of inner ear function on the affected side. Eliminates vertigo but also eliminates any remaining hearing in that ear. Reserved as a last resort for unilateral disease with no usable hearing.

For superior canal dehiscence (SSCD):

• Surgical repair (plugging or resurfacing) through either a middle cranial fossa approach or a transmastoid approach
• A large case series found the greatest symptom improvement for oscillopsia (bouncing vision), hyperacusis (sound sensitivity), and autophony (hearing one’s own voice too loudly)
• Surgery is reserved for patients with persistent, debilitating symptoms — many people with SSCD are asymptomatic and require no intervention

For acoustic neuroma (vestibular schwannoma):

• Observation (watch and wait) — Recommended for small tumors without documented growth, involving regular MRI monitoring
• Stereotactic radiosurgery — Highly focused radiation (such as Gamma Knife) that controls tumor growth in the majority of cases while avoiding open surgery
• Microsurgical resection — Open surgical removal, typically reserved for larger tumors or tumors causing significant compression of the brainstem

• What is the specific treatment plan for my diagnosed condition?
• If I have BPPV, can we do a repositioning maneuver today? Which canal is affected?
• Am I a candidate for vestibular rehabilitation therapy? Can you refer me to a vestibular-specialized physiotherapist?
• If medication is recommended, what are the expected benefits, how long until it takes effect, and what are the possible side effects?
• Am I taking any medications that could be worsening my dizziness?
• If I have been on a vestibular suppressant (meclizine), should I be tapering off to allow my brain to compensate?
• For Meniere’s disease: what step on the treatment ladder am I at, and what are the next options if this one does not work?
• Are there dietary changes that might help my specific condition?
• Under what circumstances would surgery be considered?
• How will we measure whether the treatment is working?

Dizziness is common in pregnancy and is often due to normal cardiovascular changes (low blood pressure, blood-sugar dips). But true vestibular conditions also occur — and BPPV is actually more common during and shortly after pregnancy (linked to changes in calcium metabolism and prolonged bed rest).

• Repositioning maneuvers are the safe, preferred treatment. The Epley and Semont maneuvers for BPPV use no medication and are safe in pregnancy — they are first-line.
• Most vertigo medications are limited in pregnancy. Betahistine is avoided in pregnancy (and is not FDA-approved in the US in any case). Vestibular suppressants are used sparingly and only short-term: meclizine (an older antihistamine) may be considered case-by-case with your obstetrician; benzodiazepines are generally avoided.
• Vestibular rehabilitation (exercise-based) is safe and helpful in pregnancy.
• New or severe dizziness in pregnancy should be evaluated — to exclude blood-pressure problems, anemia, or, rarely, more serious causes — rather than assumed to be “just pregnancy.”

Tell your obstetric and ENT/neurology teams you are pregnant or planning pregnancy so treatment can be tailored safely.

While many Meniere’s patients achieve good control with the initial treatment steps, some develop a chronic pattern requiring long-term management:

• Bilateral disease develops in 25–50% of patients over time, which complicates treatment because ablative options (gentamicin, labyrinthectomy) that work well for one-sided disease carry greater risk when both ears are involved.
• Progressive hearing loss is common over years, even when vertigo is controlled. Regular audiometry (hearing tests) every 6–12 months helps track changes and plan for hearing aids or other assistive devices when needed.
• Burnout period: Many patients notice that vertigo episodes become less frequent and less severe over years, while hearing loss and tinnitus may persist. This natural progression offers some reassurance for the long term.
• Psychological impact: The unpredictability of Meniere’s attacks is often as debilitating as the attacks themselves. Anxiety about when the next episode will strike can lead to activity avoidance and social withdrawal. Addressing this directly — through counseling, support groups, and sometimes medication — is an essential part of management.

Endolymphatic hydrops can now be directly visualized on specialized MRI sequences, which is improving diagnostic certainty and may eventually guide treatment decisions more precisely.

PPPD responds best to a combined approach addressing all three components simultaneously:

• Medication (SSRIs or SNRIs) — Sertraline and venlafaxine are the most studied. About 64% of patients respond, though some cannot tolerate the side effects. Starting at a very low dose and increasing slowly helps minimize initial worsening of dizziness, which is a common concern. Full benefit may take 8–12 weeks.
• Vestibular rehabilitation therapy — A 2025 meta-analysis of eight studies confirmed significant improvement in dizziness handicap scores with VRT. The habituation component is particularly important for PPPD, gradually reducing the brain’s overreaction to motion and visual stimulation.
• Cognitive behavioral therapy (CBT) — Addresses the anxiety, hypervigilance, and avoidance behaviors that perpetuate PPPD. CBT helps patients understand and modify the thought patterns and behaviors that maintain the cycle of dizziness and anxiety.

A 2025 meta-analysis of 22 studies found that combined SSRIs plus VRT produced significantly better outcomes than either treatment alone. This is a condition where teamwork between your physician, vestibular therapist, and psychologist or psychiatrist makes a real difference.

Bilateral vestibulopathy — significant loss of function in both inner ears — is one of the more challenging vestibular conditions. Causes include ototoxic medications (particularly gentamicin and cisplatin), bilateral Meniere’s disease, autoimmune inner ear disease, genetic conditions, and in roughly 50% of cases the cause is never identified.

Symptoms:

• Chronic imbalance, worse in the dark or on uneven surfaces (because without vestibular input, the brain relies more on vision and proprioception)
• Oscillopsia — the visual world appears to bounce or blur during head movement or walking (because the vestibulo-ocular reflex that normally stabilizes the eyes is impaired)
• Difficulty walking in low-light environments or with head turns

Treatment centers on intensive vestibular rehabilitation to maximize the brain’s use of remaining vestibular function and other sensory inputs. Recovery is slower and less complete than with unilateral loss, but most patients do improve with sustained rehabilitation effort.

Acoustic neuroma (vestibular schwannoma) is a benign tumor on the vestibular nerve. It is uncommon (1–2 per 100,000 per year) but important because it grows slowly and can eventually cause hearing loss, facial nerve problems, and in rare cases brainstem compression.

Three management approaches:

• Observation — For small tumors (<1.5 cm) without documented growth, regular MRI monitoring (typically every 6–12 months initially, then annually) is recommended. Many tumors grow very slowly or not at all.
• Stereotactic radiosurgery — Highly focused radiation delivered in one or a few sessions. Controls tumor growth in over 90% of cases. Hearing preservation rates are better than with open surgery for appropriately sized tumors.
• Microsurgical resection — Open surgical removal through various approaches (retrosigmoid, translabyrinthine, middle fossa). Typically chosen for larger tumors or those causing brainstem compression. Facial nerve preservation is a key goal.

The decision between these options depends on tumor size and growth rate, current hearing status, patient age and overall health, and personal preferences. A skull base tumor team — including a neurosurgeon, otologist, and radiation oncologist — provides the best multidisciplinary evaluation.

SSCD is an opening or thinning in the bone overlying the superior semicircular canal. This creates an abnormal “third window” into the inner ear that produces distinctive symptoms:

• Autophony — hearing your own voice, breathing, heartbeat, or eye movements abnormally loud
• Tullio phenomenon — vertigo or dizziness triggered by loud sounds
• Hyperacusis to bone-conducted sounds — increased sensitivity to internal sounds
• Pulsatile tinnitus — hearing your heartbeat in the affected ear
• Chronic imbalance

Diagnosis requires high-resolution CT of the temporal bones showing the dehiscence, along with concordant clinical findings and abnormal VEMP testing. Not everyone with a radiographic dehiscence is symptomatic — the finding must match the clinical picture.

Surgical repair (plugging or resurfacing the dehiscence) is highly effective for those with persistent, debilitating symptoms. For those with mild or manageable symptoms, conservative management and monitoring are reasonable.

Several promising areas of research are advancing, but it is important to be realistic about what is and is not available today:

Vestibular implant (investigational):

• Analogous to a cochlear implant but for the balance system — electrically stimulates the vestibular nerve to restore balance information
• Major research groups (Johns Hopkins, Geneva/Maastricht) have shown that implants can improve the vestibulo-ocular reflex, posture, gait, and quality of life in selected patients with bilateral vestibular loss
• The VertiGO! trial (2025) published encouraging results from a randomized cross-over study
• NOT commercially available anywhere in the world as of 2026 — still strictly investigational

Galvanic vestibular stimulation (GVS) (experimental):

• Low-intensity electrical stimulation delivered to the mastoid bones to enhance vestibular processing
• Research shows potential benefits for postural stability in various neurological conditions
• Wearable GVS devices for home-based rehabilitation are in development
• No commercially available therapeutic GVS devices — purely experimental

Virtual reality rehabilitation (growing evidence):

• VR-based vestibular rehabilitation shows promise for improving engagement and enabling home-based therapy
• A 2025 randomized trial found VR-based VRT was as effective as conventional VRT for acute vestibular loss
• Gamification improves patient motivation and compliance
• Not yet standard of care — growing evidence but not definitively superior to conventional rehabilitation

AI-based diagnostics (research only):

• Machine learning algorithms can detect nystagmus patterns for BPPV with approximately 82% accuracy in research settings
• AI-powered telehealth frameworks for remote nystagmus assessment are under development
• Not FDA-cleared for clinical diagnosis — research tools only

Hair cell regeneration (long-term research goal):

• The most publicized program, FX-322 by Frequency Therapeutics, failed its Phase 2b clinical trial and the company subsequently shut down
• Academic research continues on gene therapy (Atoh1) and stem cell approaches, but these remain in early stages
• Hair cell regeneration is a long-term research goal, not a near-term clinical option

If you have vestibular migraine, you may have heard about the newer migraine medications called CGRP inhibitors — the monthly injections (such as galcanezumab, erenumab, fremanezumab) and the oral “-gepant” tablets (such as rimegepant). These have been a genuine breakthrough for regular migraine, and there is real interest in whether they help the dizziness of vestibular migraine too. Here is an honest summary of where things stand in 2026:

• There is no drug — CGRP or otherwise — approved specifically for vestibular migraine anywhere in the world. Every medication used for it (including the older preventives like propranolol, amitriptyline, and topiramate) is borrowed “off-label” from regular migraine treatment.
• The early evidence for CGRP drugs in vestibular migraine is promising but limited. The first completed placebo-controlled trial of a CGRP injection (galcanezumab) provided an encouraging signal, and a 2025 study of the tablet rimegepant reported reduced dizziness and improved well-being within about two weeks. Larger, rigorous trials — including a placebo-controlled study of rimegepant — are underway, and their results will tell us how well these drugs really work for vertigo.
• What this means for you: CGRP drugs are a reasonable option to discuss with your doctor if the standard preventives have not worked or you cannot tolerate them. They tend to be well tolerated and avoid some of the downsides of older drugs (weight changes, cognitive fog). They are not recommended in pregnancy, and because the strongest evidence is still emerging, they are usually tried after the well-established options.

The most important point: vestibular migraine is highly treatable with the tools we already have. Identifying and managing your triggers, keeping a regular sleep and meal schedule, and giving a preventive medication an adequate trial (8–12 weeks at the right dose) help the majority of people — with or without the newest drugs.

Clinical trials are how new treatments move from the laboratory to the clinic. For patients with conditions that have not responded to standard treatments, trials may offer access to emerging therapies while contributing to medical knowledge.

• Where to search: ClinicalTrials.gov is the definitive registry. Search by your condition name and location.
• What to know: All trials have specific eligibility criteria. Participation is voluntary and can be withdrawn at any time. You will receive either the investigational treatment or the standard of care (or placebo), depending on the trial design. Your own medical team should always be involved in the decision.
• Areas of active research: CGRP monoclonal antibodies for vestibular migraine, vestibular implant refinement, gene therapy for inner ear disorders, novel drug targets for Meniere’s disease, and VR-based rehabilitation protocols.

• Is my condition likely to be chronic, and if so, what is the long-term management plan?
• For Meniere’s: is there evidence that my disease is progressing to the other ear?
• Am I a candidate for intratympanic injections or surgery?
• For PPPD: can you refer me for both VRT and CBT to combine with medication?
• Should I be monitored for hearing changes, and how often?
• Are there any clinical trials I might be eligible for?
• For acoustic neuroma: what are the risks and benefits of observation versus treatment in my specific case?
• Are any of the emerging therapies I have read about realistic options for me right now?

The most striking difference in vestibular treatment between the United States and the rest of the world involves betahistine (Serc, Betaserc):

• Not available in the US: Betahistine is not FDA-approved and is not commercially available in the United States. American patients who wish to try it must obtain it through compounding pharmacies, which is not covered by insurance.
• Widely used internationally: Betahistine is approved and widely prescribed in Europe (EMA-authorized), the UK (NICE recommends it for Meniere’s), Japan (PMDA-approved), Canada (Health Canada-approved), Australia (TGA-approved), and most other countries for Meniere’s disease.
• Evidence is mixed: The BEMED trial (2016, n=221) found no significant benefit over placebo at standard doses, but many clinicians internationally continue to prescribe it, sometimes at higher doses, based on clinical experience and individual patient response.

• United States (AAO-HNS, AAN): The AAO-HNS 2017 BPPV guideline strongly recommends canalith repositioning over vestibular suppressant medication. The AAO-HNS 2020 Meniere’s guideline covers the full treatment ladder from dietary modification through surgery. The AAN provides practice parameters for vestibular migraine diagnosis and treatment. No FDA-approved drug exists specifically for vestibular migraine.
• Europe (EMA, national bodies): The Bárány Society, headquartered in Europe, develops the internationally recognized diagnostic criteria for vestibular migraine, PPPD, and Meniere’s disease. European guidelines generally align with US recommendations but include betahistine in the Meniere’s treatment pathway. The German Society of Neurology publishes detailed vertigo and dizziness guidelines frequently referenced worldwide.
• United Kingdom (NICE, MHRA): NICE Clinical Knowledge Summaries (CKS) provide guidance on vertigo assessment and management in primary care. NICE recommends betahistine for Meniere’s. The MHRA regulates betahistine as an approved medicine. The UK uses a more structured GP referral pathway to specialist services.
• Japan (PMDA): Japan has a strong tradition of vestibular medicine with specialized “equilibrium clinics.” The Japan Society for Equilibrium Research publishes guidelines that sometimes differ in emphasis, particularly around the use of betahistine and the role of certain herbal medicines (e.g., goreisan for Meniere’s).
• Canada (Health Canada): Betahistine is approved and commonly prescribed. The Canadian Society of Otolaryngology guidelines largely align with US and Bárány Society recommendations. Vestibular rehabilitation is widely available through publicly funded physiotherapy services.
• Australia (TGA): Betahistine is available by prescription. The Meniere’s Research Fund Australia supports research and patient education. Australian guidelines generally follow international consensus with attention to rural and remote access challenges.

• Betahistine: Available in Europe, UK, Japan, Canada, Australia, and most of the world. Not FDA-approved in the US (available only through compounding pharmacies).
• Cinnarizine and Cinnarizine/Dimenhydrinate combinations: Used in Europe and parts of Asia for vertigo and motion sickness. Not available in the US.
• Goreisan (Gorei-san): A traditional Japanese herbal medicine (Kampo) used in Japan for Meniere’s disease. Covered by Japanese national health insurance. Not regulated as a medicine in the US or Europe.
• Intratympanic gentamicin: Used worldwide but with varying levels of guideline support. The AAO-HNS 2020 guideline includes it in the Meniere’s treatment ladder. Some European centers have moved away from it due to hearing loss risk, preferring intratympanic dexamethasone.

• Traveling with a vestibular condition: Carry a written summary of your diagnosis, current medications, and treatment plan in English and the local language. Some vestibular suppressant medications may have different brand names in other countries.
• Vestibular Disorders Association (VeDA): Provides a global provider directory and resources in multiple languages at vestibular.org.
• Bárány Society: The international body that sets vestibular diagnostic criteria. Its member list can help identify vestibular specialists in various countries.

Falls are the leading cause of injury-related death in adults aged 65 and older, and balance disorders substantially increase the risk. Many falls are preventable with straightforward modifications:

Home safety:

• Install grab bars in the bathroom — next to the toilet, inside the shower or tub, and at the tub entry. This is the single most important home modification.
• Improve lighting throughout the home, especially in hallways, staircases, and bathrooms. Use nightlights for nighttime navigation.
• Remove loose rugs or secure them with non-slip backing. Area rugs are a leading cause of household falls.
• Keep pathways clear of clutter, cords, and low furniture.
• Add non-slip strips or mats in the bathtub and shower.
• Install handrails on both sides of all stairways.
• Keep frequently used items at waist height to avoid reaching up or bending down.
• Consider a shower bench or chair if standing in the shower is unsteady.

Personal safety:

• Wear well-fitting shoes with low heels and non-slip soles, even indoors. Avoid walking in socks or loose slippers.
• Use a cane or walker if recommended — there is no shame in using an assistive device, and the independence it preserves far outweighs any self-consciousness.
• Rise slowly from sitting or lying down, especially in the morning or after meals.
• Keep a phone within reach at all times. Consider a medical alert system if you live alone.

Regular exercise is one of the most effective interventions for improving balance and preventing falls. Several evidence-based programs have been specifically studied:

• Otago Exercise Program (OEP) — A home-based program combining strength exercises, balance challenges, and a walking plan. A 2025 meta-analysis confirmed its effectiveness for fall prevention, improved balance function, and reduced fear of falling. Can be taught by a physiotherapist and performed independently at home.
• Tai Chi — Strong evidence supports Tai Chi for fall prevention in older adults. The USPSTF recommends exercise interventions including Tai Chi for community-dwelling adults aged 65 and older who are at increased fall risk. The slow, controlled movements improve balance, leg strength, and body awareness.
• Walking programs — Regular walking (30 minutes, most days) improves cardiovascular fitness, leg strength, and confidence in mobility. Start with flat, even surfaces and progress to more challenging terrain as balance improves.
• General strength training — Leg strength is directly linked to fall risk. Exercises targeting the quadriceps, hamstrings, calves, and hip muscles help maintain the ability to catch yourself if you stumble.

The CDC’s STEADI (Stopping Elderly Accidents, Deaths & Injuries) toolkit provides a risk assessment framework that your primary care doctor can use to evaluate your fall risk and recommend targeted interventions.

Beyond specific exercises, the everyday rhythms of life have a real effect on balance and dizziness — especially for vestibular migraine, Meniere’s disease, and PPPD, all of which are sensitive to the body’s internal stability. Small, consistent habits often add up to fewer and milder episodes:

• Keep a regular sleep schedule. Both too little and too much sleep, and irregular timing, are powerful migraine and dizziness triggers. Aim for consistent bed and wake times, even on weekends.
• Do not skip meals, and stay hydrated. Blood-sugar dips and dehydration both provoke dizziness and migraine. Eat at regular intervals and keep water within reach through the day. For Meniere’s disease, spreading fluids evenly and limiting salt is part of the standard plan.
• Be deliberate with caffeine and alcohol. Both can worsen vertigo and migraine in sensitive people. You do not necessarily have to eliminate them, but notice whether they track with your bad days — a simple diary reveals patterns quickly.
• Manage stress actively. Stress and anxiety amplify dizziness through the same brain pathways involved in PPPD. Regular relaxation practice — breathing exercises, mindfulness, gentle yoga, or simply protected downtime — is not a luxury; for many people it measurably reduces symptoms.
• Keep moving. It is tempting to rest and avoid movement when dizzy, but prolonged inactivity weakens balance and slows the brain’s adaptation. Within your safe limits, daily walking and the exercises your therapist prescribes are part of the treatment.
• Get your vision and hearing checked. Balance relies on a partnership of senses; up-to-date glasses and, where needed, hearing aids reduce the load on the inner ear and lower fall risk.

None of these replaces medical treatment, but together they create the stable foundation on which repositioning, rehabilitation, and medication work best. Keeping a brief symptom-and-trigger diary for a few weeks is one of the most useful things you can do — it turns vague impressions into clear patterns you and your doctor can act on.

Driving is a sensitive but important topic for people with balance disorders:

• During acute vertigo episodes: Do not drive. Period. Acute vertigo impairs reaction time, spatial awareness, and the ability to safely control a vehicle.
• Between episodes: Many people with well-controlled vestibular conditions (such as treated BPPV or medically managed vestibular migraine) can drive safely. The key question is whether episodes occur without warning.
• Chronic imbalance without vertigo: This may not impair driving ability, but an individual assessment is important.
• After vestibular surgery or an acute event: Follow your doctor’s specific guidance on when it is safe to resume driving. This typically means waiting until the acute symptoms have resolved and you can demonstrate safe head movements and reaction times.

Discuss driving honestly with your doctor. Some jurisdictions have mandatory reporting requirements for conditions that impair driving safety. Being proactive about this discussion protects both you and others.

One of the most common and underappreciated consequences of vestibular disorders is the development of avoidance behavior and anxiety. After experiencing a terrifying vertigo episode, it is entirely natural to fear another one. But this fear can become a problem in itself:

• Activity avoidance — Avoiding movements, environments, or activities that you associate with dizziness. While understandable, this actually worsens outcomes by preventing the brain from adapting and by reducing physical fitness.
• Hypervigilance — Constantly monitoring your body for signs of an approaching episode. This heightened awareness can itself trigger dizziness sensations (a key component of PPPD).
• Social withdrawal — Avoiding social situations, restaurants, shopping, or travel due to fear of an episode in public. This leads to isolation and depression.

What helps:

• Gradual, supported re-exposure to avoided activities — this is a core component of both vestibular rehabilitation and cognitive behavioral therapy
• Understanding that some movement-triggered dizziness during rehabilitation is expected and not dangerous
• Cognitive behavioral therapy (CBT) specifically adapted for vestibular disorders
• Mindfulness-based stress reduction
• Support groups where others understand the experience

Vestibular disorders affect daily functioning in ways that are often invisible to others. Practical adaptations can help:

• At work: Consider requesting accommodations such as a stable (non-rolling) desk chair, reduced screen time with regular breaks, adequate lighting, and the ability to work in a quieter area during symptomatic periods. In many jurisdictions, vestibular disorders may qualify for reasonable workplace accommodations.
• Screen use: Scrolling screens, rapid visual movement, and prolonged computer use can worsen symptoms for many vestibular patients. Take regular breaks (the 20-20-20 rule: every 20 minutes, look at something 20 feet away for 20 seconds), reduce screen brightness, and consider motion-reducing settings on your devices.
• Shopping and busy environments: Grocery stores, malls, and airports can be particularly challenging due to complex visual patterns, fluorescent lighting, and crowded movement. Strategies include shopping during quieter hours, using a cart for stability, wearing tinted glasses if fluorescent light is a trigger, and taking breaks when needed.
• Travel: Plan for rest periods, carry prescribed medications, choose aisle seats on planes, and consider window seats on trains. Inform travel companions about your condition and what to do during an episode.

The psychological burden of balance disorders is significant and often underrecognized:

• Anxiety and depression are highly comorbid with vestibular disorders — not because the dizziness is “caused by anxiety,” but because living with an unpredictable, disabling, invisible condition is inherently stressful
• Many patients report that others — including some healthcare providers — do not take their symptoms seriously because there is nothing visibly wrong
• The invisible nature of dizziness means that friends, family, and colleagues may not understand why you cannot do things you used to do
• Grief for lost activities, independence, and spontaneity is common and valid

What helps:

• Screening for anxiety and depression (ask your doctor about the PHQ-9 and GAD-7 screening tools)
• Therapy with a psychologist or counselor experienced in chronic health conditions — CBT is particularly well-suited
• Support groups (the Vestibular Disorders Association runs online communities)
• Open communication with family and close friends about what you are experiencing
• Medication for anxiety or depression when appropriate, ideally coordinated with your vestibular treatment plan

• What specific exercises should I be doing at home to improve my balance and reduce fall risk?
• Should I be using a cane or other assistive device?
• Is it safe for me to drive, and under what conditions?
• My anxiety about dizziness is affecting my daily life — can you refer me for psychological support?
• Should my home be assessed for fall hazards?
• Are there workplace accommodations I should request?
• How much physical activity is safe and recommended for my condition?
• Could any of my medications be increasing my fall risk?

FAILED

Betahistine (Serc) is widely prescribed in Europe and elsewhere for vertigo, but multiple randomized controlled trials and a large Cochrane review have failed to demonstrate meaningful benefit for BPPV specifically. The BEMED trial (2016), one of the largest randomized studies of betahistine for Meniere’s disease, also found no significant difference from placebo on vertigo attack frequency. Despite ongoing use in some countries, evidence-based guidelines emphasize that canalith repositioning maneuvers — not medication — are the appropriate first-line treatment for BPPV. Betahistine is not approved by the US FDA for any indication.

DE-ADOPTED

Vestibular nerve section (selective surgical cutting of the vestibular nerve while preserving hearing) was once considered the gold standard surgical treatment for refractory Meniere’s disease. While effective at eliminating vertigo in approximately 90–95% of cases, it is a major intracranial procedure requiring craniotomy, carrying risks of cerebrospinal fluid leak, meningitis, facial nerve injury, and hearing loss. With the advent of intratympanic gentamicin injection — which achieves comparable vertigo control rates (approximately 80–90%) with far less invasive office-based delivery — vestibular nerve section has been largely abandoned at most centers worldwide. It remains available at a small number of specialized centers for the rare cases that fail all other therapies.

DE-ADOPTED

Cinnarizine and flunarizine are calcium channel blockers that were widely used in Europe and Asia for decades as primary treatments for vertigo of various causes. While they have some modest anti-vertiginous effect, their long-term use has been associated with significant adverse effects including parkinsonism, depression, and weight gain — particularly in elderly patients. The European Medicines Agency issued safety warnings, and many vestibular specialists now restrict their use to short courses for vestibular migraine prophylaxis only, favoring better-tolerated alternatives. Neither drug is approved in the United States or Canada.

FAILED

Endolymphatic sac decompression and shunt surgery was performed for decades on the theory that draining excess endolymph would relieve Meniere’s vertigo attacks. However, a landmark sham-controlled trial by Thomsen et al. (1981) found that a simple mastoidectomy (the sham procedure) produced the same improvement rates as the actual endolymphatic sac procedure. Subsequent reviews and the AAO-HNS Meniere’s clinical practice guideline note the lack of high-quality evidence supporting its efficacy. While some surgeons continue to offer this procedure and retrospective case series report benefit, the absence of confirmed superiority over placebo surgery has led many centers to deprioritize it in favor of intratympanic therapy and vestibular rehabilitation.

DE-ADOPTED

Benzodiazepines (such as diazepam, lorazepam, and clonazepam) were historically prescribed as long-term vestibular suppressants for chronic dizziness. While they can provide short-term symptomatic relief during acute vertigo attacks, evidence now clearly shows that chronic use is harmful for vestibular patients. Benzodiazepines suppress the brain’s natural vestibular compensation process, effectively preventing recovery. They also cause sedation, cognitive impairment, falls risk (particularly in elderly patients), dependence, and withdrawal symptoms. Current guidelines from the AAO-HNS, the Barany Society, and vestibular rehabilitation experts strongly advise against long-term benzodiazepine use and recommend limiting their use to brief courses (days, not weeks) for acute episodes only.

FAILED

OTO-104 was a sustained-release formulation of dexamethasone in a poloxamer gel, developed by Otonomy Inc. for intratympanic injection in Meniere’s disease. It was designed to provide prolonged steroid exposure to the inner ear from a single injection. The Phase 3 clinical trial failed to meet its primary endpoint of reducing vertigo frequency compared to placebo. Otonomy subsequently discontinued development for this indication. The failure highlighted the ongoing challenge of demonstrating drug efficacy in Meniere’s disease, a condition with high placebo response rates and natural fluctuations in symptom frequency.

WITHDRAWN

The Meniett device delivered low-pressure micropulses to the middle ear through a tympanostomy tube, based on the theory that pressure changes could improve endolymphatic fluid dynamics in Meniere’s disease. While initial small studies showed some promise, larger and better-controlled trials produced mixed results, and a Cochrane review concluded that evidence for efficacy was insufficient. The manufacturer (Medtronic) discontinued the device commercially, citing limited uptake and inconclusive evidence. Patients who received tympanostomy tubes for device use were also exposed to the risks of the tube itself (infection, persistent perforation) without clear benefit from the pressure therapy.

Balance disorders sit at the intersection of several medical specialties. Understanding who does what helps you seek the right help:

• ENT (Otolaryngologist) — Ear, nose, and throat specialist. Most vestibular conditions begin here. An ENT can diagnose BPPV, Meniere’s disease, vestibular neuritis, acoustic neuroma, and SSCD, and can perform repositioning maneuvers and intratympanic injections.
• Neuro-otologist / Neurotologist — A subspecialist with additional fellowship training in disorders of the ear and its connections to the brain. For complex or refractory cases, this is the most specialized clinician available.
• Audiologist — Performs hearing tests and vestibular testing (VNG, vHIT, VEMP). Essential for diagnosis and monitoring.
• Vestibular physiotherapist — A physical therapist with specialized training in vestibular rehabilitation. Not all physical therapists have this training — look for credentials in vestibular therapy or ask VeDA’s provider directory.
• Neurologist — Important for vestibular migraine, central causes of vertigo, and when stroke or multiple sclerosis needs to be excluded.
• Psychologist or psychiatrist — For PPPD, anxiety, depression, or the emotional impact of chronic vestibular disease. CBT-trained therapists are particularly valuable.
• Primary care physician — Coordinates overall care, manages medications that may contribute to dizziness, and provides falls risk assessment.

• University of Utah Health — Otolaryngology & Vestibular/Balance Clinic — Comprehensive vestibular evaluation, BPPV repositioning, Meniere’s management, intratympanic injections, skull base tumor program for acoustic neuroma, and SSCD surgical repair. Academic tertiary referral center with clinical trial participation. Phone: 801-581-2121 (main), 801-585-6387 (Neurosciences).
• University of Utah Audiology — Vestibular Testing Lab — Full vestibular testing battery including VNG, vHIT, VEMP, rotary chair, computerized dynamic posturography, and comprehensive audiometry. Phone: 801-581-2352 (Moran Eye Center, which also houses neuro-ophthalmology for vestibular-visual assessment).
• Intermountain Health ENT Services — Multiple locations along the Wasatch Front offering ENT evaluation, vestibular testing, and BPPV management. Community-based referral option. Phone: 801-442-2000 (main).
• University of Utah Department of Neurology — Expertise in vestibular migraine, central causes of vertigo, and neurological dizziness. Headache and vestibular migraine subspecialty clinic. Phone: 801-585-6387 (Neurosciences).
• University of Utah Physical Therapy — Vestibular Rehabilitation — Specialized vestibular physiotherapists offering gaze stabilization, habituation, balance retraining, concussion rehabilitation, and falls prevention programs.
• Utah Falls Prevention Coalition — Statewide initiative coordinating falls prevention resources, community exercise programs, home safety assessments, and education for older adults.

• George E. Wahlen VA Medical Center (Salt Lake City) — Audiology and vestibular evaluation services, vestibular rehabilitation, ENT consultation, and falls prevention programs for eligible veterans. Phone: 801-582-1565.
• VA Audiology & Vestibular Programs — The VA system is one of the largest providers of vestibular rehabilitation in the United States. Veterans with service-connected hearing loss or balance disorders may qualify for comprehensive vestibular care at no cost. Contact your local VA enrollment coordinator or call the VA Health Benefits Hotline at 1-877-222-8387.

• Johns Hopkins Vestibular Disorders Center (Baltimore, MD) — One of the world’s leading vestibular research and clinical programs. Vestibular implant research, comprehensive vestibular evaluation, skull base surgery. Phone: 410-955-5000.
• Massachusetts Eye and Ear — Vestibular Division (Boston, MA) — Harvard-affiliated center with expertise in all vestibular disorders, SSCD repair, and acoustic neuroma management. Phone: 617-523-7900.
• Mayo Clinic — Vestibular & Balance Program (Rochester, MN) — Multidisciplinary vestibular evaluation and treatment with integrated audiology, neurology, and otolaryngology. Phone: 507-284-2511.
• UCLA Vestibular & Balance Disorders Program (Los Angeles, CA) — Comprehensive vestibular diagnostic and treatment services, skull base tumor program. Phone: 310-825-9111.
• House Ear Institute / House Clinic (Los Angeles, CA) — Pioneering center for otologic surgery including acoustic neuroma, Meniere’s disease, and SSCD. Phone: 213-483-9930.

• Sunnybrook Health Sciences Centre — Otology & Neurotology Program (Toronto, ON) — One of Canada’s largest vestibular clinical and research programs, including cochlear implant and skull base surgery.
• Toronto General Hospital / University Health Network — Balance Clinic (Toronto, ON) — Comprehensive vestibular evaluation and rehabilitation within a multidisciplinary setting.
• McGill University Health Centre — Otolaryngology (Montreal, QC) — Vestibular evaluation, Meniere’s management, and vestibular schwannoma treatment. Bilingual services.
• Vancouver General Hospital / UBC — Otolaryngology (Vancouver, BC) — Vestibular disorders evaluation and treatment, integrated with UBC research programs.
• Note: Betahistine is approved by Health Canada and commonly prescribed. Vestibular rehabilitation is available through publicly funded physiotherapy services in most provinces.

• United Kingdom:
  • National Hospital for Neurology and Neurosurgery — Queen Square Neuro-otology Unit (London) — One of the world’s foremost centers for complex vestibular disorders, PPPD, and vestibular migraine research.
  • Manchester University NHS Foundation Trust — Auditory & Vestibular Medicine (Manchester) — Dedicated vestibular and balance service with integrated rehabilitation.
• Europe:
  • German Center for Vertigo and Balance Disorders — DSGZ (Munich, Germany) — The largest dedicated dizziness center in Europe, co-locating neurology, otolaryngology, psychiatry, and vestibular rehabilitation in one facility. Internationally recognized research program.
  • Geneva University Hospitals / Maastricht UMC+ — Vestibular Implant Program (Switzerland / Netherlands) — Joint program leading the VertiGO! vestibular implant trial for bilateral vestibulopathy.
• Asia-Pacific:
  • University of Tokyo Hospital — Equilibrium Clinic (Tokyo, Japan) — Japan has a strong tradition of dedicated vestibular clinics. Leading center for Meniere’s disease research and treatment, including Kampo (traditional Japanese medicine) approaches.
  • Seoul National University Hospital — Dizziness Center (Seoul, South Korea) — Large-volume vestibular diagnostic and treatment center with an integrated research program.

• VeDA (Vestibular Disorders Association) — vestibular.org — The leading patient advocacy organization for vestibular disorders. Offers educational resources, a provider directory (including vestibular physiotherapists), online support communities, and a helpline. An excellent starting point for newly diagnosed patients.
• American Academy of Neurology (AAN) — aan.com — Practice guidelines for vestibular migraine and other neurological causes of dizziness.
• American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS) — entnet.org — Clinical practice guidelines for BPPV and Meniere’s disease, and a physician finder tool.
• Acoustic Neuroma Association (ANA) — anausa.org — Resources and support specifically for patients with vestibular schwannoma.
• Meniere’s Society — menieres.org.uk — UK-based organization with internationally relevant educational materials and support.
• CDC STEADI Initiative — cdc.gov/steadi — Falls prevention resources for older adults and their healthcare providers.

Navigating the financial aspects of vestibular care can be challenging:

• Vestibular testing is typically covered by insurance when ordered by a physician, but check with your plan about specific tests and in-network providers.
• Vestibular rehabilitation is covered by most insurance plans as physical therapy, but the number of allowed sessions may be limited. Ask your therapist to help document medical necessity for continued treatment if more sessions are needed.
• Medications: Betahistine obtained through compounding pharmacies is not typically covered by insurance since it is not FDA-approved. Migraine preventives and SSRIs are generally covered.
• MRI scans may require prior authorization. Your ordering physician’s office typically handles this, but follow up to avoid delays.
• If you are uninsured or underinsured: University hospital systems often have financial assistance programs. Community health centers may offer sliding-scale fees. The VeDA website lists additional financial resources.

If you have a condition that causes sudden vertigo episodes, being prepared reduces both the risk and the anxiety:

• Carry anti-nausea medication (ondansetron or promethazine, as prescribed) and know where it is at all times.
• Have a plan for acute episodes in public: Sit or lie down immediately if possible. Have the phone number of someone who can come get you. Know the location of the nearest emergency department.
• Inform people you spend time with — family, close friends, coworkers — about your condition and what to do if you have an episode. This reduces the panic for everyone involved.
• Keep a medical summary card in your wallet with your diagnosis, medications, allergies, and emergency contact. This is invaluable if you are too symptomatic to communicate clearly.
• If you live alone: Consider a medical alert system (wearable or phone-based). Establish a daily check-in system with a friend or family member.

• Can you refer me to a neuro-otologist or neurotologist for my condition?
• Is there a vestibular-specialized physiotherapist you recommend?
• Should I be seeing a neurologist in addition to my ENT?
• Would a psychologist or counselor be helpful for managing the emotional impact of my condition?
• How often should I have follow-up appointments and hearing tests?
• What should I do if I experience a sudden change in symptoms between appointments?
• Are there any clinical trials at this center or nearby that I should know about?
• Can you write a letter supporting workplace accommodations if I need one?
• What is the long-term outlook for my specific condition?

• BPPV (benign paroxysmal positional vertigo) — The most common cause of vertigo, triggered when tiny calcium crystals (otoconia) become dislodged and float into the wrong part of the inner ear. Brief spinning episodes are typically set off by changes in head position such as rolling over in bed or looking up.
• Vestibular neuritis — An inflammation of the vestibular nerve, usually caused by a viral infection, that produces sudden, severe vertigo lasting days to weeks. Hearing is typically unaffected, which helps distinguish it from other inner-ear conditions.
• Meniere disease — A chronic inner-ear disorder characterized by episodes of vertigo, fluctuating hearing loss, tinnitus (ringing), and a feeling of fullness or pressure in the ear. It is thought to result from abnormal fluid buildup in the inner ear.
• Vestibular migraine — A type of migraine that causes dizziness or vertigo rather than (or in addition to) a headache. Episodes can last minutes to days and may be accompanied by light sensitivity, nausea, or visual changes.
• PPPD (persistent postural-perceptual dizziness) — A functional dizziness disorder in which the brain remains stuck in a high-alert balance mode long after an original trigger has resolved. Symptoms include chronic unsteadiness, swaying sensations, and increased dizziness in visually busy environments.
• HINTS exam — A three-part bedside test (Head Impulse, Nystagmus, Test of Skew) used by clinicians to distinguish a harmless inner-ear cause of vertigo from a potentially dangerous stroke in the brainstem or cerebellum.
• Dix-Hallpike test — A simple clinical maneuver in which the head is turned to one side and the patient is quickly moved from sitting to lying back. It is the standard test used to diagnose BPPV by provoking characteristic eye movements (nystagmus).
• Epley maneuver — A sequence of guided head and body movements performed to reposition dislodged crystals in the inner ear back to where they belong. It is the primary treatment for BPPV and resolves symptoms in most people within one to two sessions.
• VRT (vestibular rehabilitation therapy) — A specialized form of physical therapy that uses targeted exercises to retrain the brain's ability to process balance signals. It is one of the most effective treatments for many types of chronic dizziness and imbalance.
• Nystagmus — Involuntary, rhythmic eye movements that can be observed during a vertigo episode or provoked by clinical tests. The direction, pattern, and behavior of nystagmus help doctors determine the cause and location of a balance problem.
• Otolith — Tiny calcium carbonate crystals in the inner ear that sit on sensory hair cells and help detect gravity and straight-line movement such as going up in an elevator. When these crystals become displaced, they can cause BPPV.
• Caloric testing — A diagnostic test in which warm or cool water (or air) is introduced into the ear canal to stimulate the inner ear and measure the response of each side independently. It helps determine whether one ear's balance function is weaker than the other.
• Videonystagmography (VNG) — A set of tests that use infrared goggles to record eye movements while the patient follows visual targets, changes head position, or undergoes caloric stimulation. It is one of the most common and informative tests for evaluating the balance system.
• Betahistine — A medication widely prescribed outside the United States to reduce the frequency and severity of vertigo attacks in Meniere disease. It is thought to work by improving blood flow in the inner ear and modulating histamine receptors involved in balance signaling.